Cancer is the leading cause of death in the USA, and the incidence of cancer increases dramatically with age. Beta-adrenergic blockers appear to have a beneficial clinical effect in cancer patients. In this paper, we review the evidence of an association between β-adrenergic blockade and cancer. Genetic studies have provided the opportunity to determine which proteins link β-adrenergic blockade to cancer pathology. In particular, this link involves the major histocompatibility complex class II molecules, the renin-angiotensin system, transcription factor nuclear factor-kappa-light-chain-enhancer of activated B cells, poly(ADP-ribose) polymerase-1, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate oxidase. Beta-adrenergic blockers also exert anticancer effects through non-genomic factors, including matrix metalloproteinase, mitogen-activated protein kinase pathways, prostaglandins, cyclooxygenase-2, oxidative stress, and nitric oxide synthase. In conclusion, β-adrenergic blockade may play a beneficial role in cancer treatment. Additional investigations that examine β-adrenergic blockers as cancer therapeutics are required to further elucidate this role.
Introduction
The relationship between β-adrenergic antagonism and cancer has been well established in the literature. The function of β-adrenergic receptors was demonstrated in the cell membranes of breast cancer cells by the significant increase in cyclic adenosine monophosphate (cAMP) production induced by different concentrations of isoproterenol compared with cells that were unstimulated (control). 1 Further, β-adrenergic receptors were implicated in the regulation of cell growth in lung cancer cell lines via the cAMP signaling pathway. 2, 3 Beta-adrenergic receptors were more highly expressed in oral squamous-cell carcinomas than in normal controls cells, and their expression was correlated with cervical lymph node metastasis, age, tumor size, and clinical stage. 4 The β 2 -adrenergic receptor density in hepatocellular carcinoma (HCC) cellular membranes was higher than the β 2 -adrenergic receptor density in nonadjacent non-tumor liver cell membranes. 5 Isoproterenol significantly increased cell proliferation via β-adrenergic receptors in a dose-dependent manner, with the concomitant activation of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway in pancreatic cancer cells. 6 In several experimental cancer models, the activation of the sympathetic nervous system promotes the metastasis of solid epithelial tumors and the dissemination of hematopoietic malignancies via the β-adrenoreceptor-mediated activation of protein kinase A (PKA) and the activation of exchange proteins by the adenylate cyclase signaling pathways. Interestingly, common haplotypes of the β 2 -adrenergic receptor, which affect its translational efficiency, are associated with longevity in men and the level of β 2 -adrenergic receptor protein is inversely associated with male lifespan. 7 These findings may well have clinical implications for treating patients with β-adrenergic receptor agonists or antagonists.
Beta-blockers, used in a clinical context, reduced the rates of progression of several solid tumors. 8 Chronic stress can accelerate the progression of human acute lymphoblastic leukemia via β-adrenergic signaling. 9 Psychological stress promotes the progression of pancreatic cancer xenografts via neurotransmitter-induced activation of multiple pathways and increases systemic and tumor levels of norepinephrine (NE), epinephrine, cortisol, vascular endothelial growth factor (VEGF), and cAMP. 10 Social stress also stimulates non-small cell lung carcinoma (NSCLC) by increasing nicotinic acetylcholine receptor-mediated stress neurotransmitter signaling. 11 These findings are consistent with sympathetic effects on cell growth in cancer.
Epinephrine significantly increased the esophageal squamous-cell carcinoma cell proliferation that accompanied the elevation of intracellular cAMP levels, which were decreased by β-adrenergic antagonists. 12 The development of lumbar lymph node metastases of human prostate cancer cells in athymic BALB/c nude mice increased with the application of NE via micro-osmotic pumps, and propranolol inhibited this effect. 13 Exposure to nicotine either by tobacco smoke or nicotine supplements facilitates the growth and progression of NSCLC, and pharmacological intervention with β-blockers may lower the risk of NSCLC development among smokers. 14 In elderly malnourished cancer patients, atenolol and propranolol treatment reduced resting energy expenditure, 15 and propranolol decreased patient's basal metabolic rates. 16 Beta-blockers have also been associated with reduced prostate cancer-specific mortality, a 54% reduction in epithelial ovarian cancer death, a reduced risk in progression of thick malignant melanoma, the inhibition of astrocytoma cell proliferation, the induction of human gastric cancer cell apoptosis, the stimulation of cell cycle arrest, and the prevention of pancreatic cancer. [17] [18] [19] [20] [21] [22] In breast cancer, β-blocker use improved relapse-free survival in all patients with breast cancer; this effect was particular pronounced in patients with triple-negative breast cancer. The use of β-blockers resulted in a 57% reduction in the risk of metastasis and a 71% reduction in the 10-year mortality rate, and β-blockers could potentially be administered concomitantly with chemotherapy to increase treatment efficacy in breast cancer patients. [23] [24] [25] [26] Following β-adrenergic-receptor stimulation, receptor activator of nuclear factor kappa-B ligand (RANKL) expression was induced in bone marrow osteoblasts and increased the migration of metastatic breast cancer MDA-231 cells in vitro. Further, RANKL expression can be blocked with the β-blocker propranolol in MDA-231 cells. Beta-blockers and drugs that interfere with RANKL signaling, such as denosumab, could increase patient survival if used as an adjuvant therapy to inhibit the early colonization of bone by metastatic breast cancer cells. 27 In a retrospective study, propranolol treatment decreased the incidence of HCC in patients with compensated hepatitis C virus cirrhosis.
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Carvedilol was a very potent inhibitor of cell proliferation in cells derived from breast tumors (MDA-MB-361), melanoma (Fem-x), cervix adenocarcinomas (HeLa) and human myelogenous leukemia. 29 In addition, ICI 118551, a β 2 -adrenoceptor blocker, significantly synergized the antiproliferative and pro-apoptotic effects induced by gemcitabine to inhibit the proliferation of pancreatic cancer cells. 30 The use of propranolol as an adjunctive treatment has been reported for severe recurrent respiratory papillomatosis. 31 Propranolol enhanced the sensitivity of gastric cancer cells to radiation by inhibiting β-adrenergic receptors and the downstream nuclear factor kappa-B cells (NF-κB)-VEGF/epidermal growth factor receptor/cyclooxygenase (COX)-2 pathway. 32 Propranolol also had antiproliferative and apoptotic effects on multiple myeloma cells. 33 These findings suggest that β-adrenergic blockade might play a role in cancer treatment.
Based on the evidence described above, in this review, we discuss the role of β-adrenergic blockers in cancer. Figure 1 illustrates the signaling pathways and their connections to β-adrenergic receptors.
malignancies at a high frequency. 34 Most of these neoplasms were highly similar to the types of neoplasms that are found in human diseases. HLA-DR antigen expression was correlated with histopathological type and with the degree of cell differentiation in cutaneous squamous-cell carcinomas. 35 In southern Tunisia, the DRB1*03 and DR-B1*13 alleles were significantly more frequent in patients with nasopharyngeal carcinoma (NPC). 36 The DR1 gene was shown to be strongly associated with thyroid carcinoma.
37 HLA-DR was also increased in poorly differentiated thyroid carcinoma and in the anaplastic type of this carcinoma in particular. 38 In Chinese populations, the DQA1*0102 and DPB1*0501 alleles have been reported to be significantly more common in patients with HCC than in controls. 39 Among Korean study populations, the frequency of the DRB1*0404 allele was significantly higher in gastric cancer patients than in gastritis patients. 40 However, the frequencies of the DRB1*0405 and DQB1*0401 alleles were increased in Japanese patients with intestinal-type gastric cancer compared with controls. 41 Somatic mutations affecting HLA class II genes may lead to a loss of HLA class II expression due to the formation of microsatellites in unstable colorectal carcinomas (CRCs). 42 The DRB1*15 allele and the DRB1*15 DQB1*0602 haplotype have been associated with human papillomavirus-16 positive invasive cervical cancer in Mexican women. 43 It has been demonstrated that the DRB1*0410 allele is the susceptibility allele in Japanese patients with testicular germ cell carcinoma. 44 Furthermore, the frequencies of the DRB1*09 and DQB1*03 alleles were increased in patients with non-Hodgkin's lymphoma and diffuse large B-cell lymphoma compared with normal controls. 45 In a study of Turkish children, the frequencies of the DRB1*04 and DRB1*15 alleles were significantly higher in patients with acute leukemia than in controls. 46 In Eastern Canada, the DRB1*16 allele was a marker for a significant risk of chronic myelogenous leukemia. 47 The DRB1*04 and DRB5 alleles were associated with disease progression in Iranian patients with chronic lymphocytic leukemia. 48 Moreover, cardiac β-adrenergic receptors and adenylate cyclase activity in dilated cardiomyopathy were shown to be modulated by circulating autoantibodies against the cardiac β 1 -adrenoceptor; the presence of these autoantibodies is controlled by the HLA-DR. 49 Furthermore, propranolol-abrogated interferongamma increased HLA class II expression and interleukin-1-beta (IL-1β) secretion. 50 HLA-DR was significantly reduced in the lymphocytes of carvedilol-treated chronic heart failure patients. 51 These findings suggest that β-adrenergic blockers may have an effect on cancer by suppressing the expression of MHC class II antigens.
The primary function of the renin-angiotensin system (RAS) is to maintain fluid homeostasis and regulate blood pressure. The angiotensin-converting enzyme (ACE) is a key enzyme in the RAS that converts angiotensin (AT) I to the potent vasoconstrictor AT II. 52 The local RAS may influence tissue angiogenesis, cellular proliferation, apoptosis, and inflammation. 53 Epidemiological and experimental studies have suggested that the RAS might contribute to the paracrine regulation of tumor growth. Renin levels are elevated in patients with liver cirrhosis and HCC and have been positively correlated with α-fetoprotein. 54 The overexpression 
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of ACE has been reported in extra-hepatic cholangio-carcinoma, 55 leukemic myeloid blast cells, 56 and macrophages in the lymph nodes of Hodgkin's disease patients. 57 AT II receptors were also shown to be expressed in all human gastric cancer lines, 58 premalignant and malignant prostate cells, 59 human lung cancer xenografts, 60 and ovarian cancer. 61 The RAS mutation in codon 61 was the most common genetic alteration in poorly differentiated thyroid carcinomas. 62 The ACE I/D polymorphism has been identified as a possible target for developing genetic markers for breast cancer in Brazilian women. 63 The ACE I/D polymorphisms were shown to play an important role in breast cancer risk and disease-free survival in Caucasian postmenopausal women. 64 Carriers of the high-activity DD genotype exhibited an increased risk of breast cancer compared with low activity II/ID genotype carriers. 65 The DD genotype was associated with patients with an aggressive stage of prostate cancer.
66
ACE2 expression was decreased in NSCLC and in pancreatic ductal adenocarcinoma, in which AT II levels were higher than in controls. 67, 68 ACE2 has been suggested as a potential molecular target for pancreatic cancer therapy. 69 The AT II concentration was significantly higher in the gastric cancer region than in adjacent tissue. 70 Furthermore, angiotensin II-receptor blockers suppressed the cell proliferation effects of AT II in breast cancer cells. 71 The addition of ACE inhibitors or angiotensin II-receptor blockers to platinum-based first-line chemotherapy contributed to prolonged survival in patients with advanced lung cancer 72 and positively affected the prognosis of advanced pancreatic cancer patients receiving gemcitabine. 73 RAS inhibitors also improved the outcome of sunitinib treatment in metastatic renal cell carcinoma. 74 Moreover, catecholamines can alter the release of AT II. Ming et al 75 demonstrated that isoproterenol enhances the stimulatory effect of dexamethasone on the expression of the AT gene via β 2 -adrenergic receptors in mouse hepatoma cells. Isoproterenol promoted an increase in the release of AT II from isolated perfused mesenteric arteries, and this release was blocked by propranolol. 76 In other studies, isoproterenol also increased the secretion of AT II in neuronal cultures, cultured bovine aortic endothelial cells, and the brachial arteries of hypertensive subjects. [77] [78] [79] Propranolol treatment reduced plasma renin activity, AT I, AT II, and AT [1] [2] [3] [4] [5] [6] [7] in the portal vein and periphery in cirrhotic patients compared with non-treated patients. 80 Carvedilol inhibited basal and stimulated ACE production in human endothelial cells 81 and exhibited beneficial effects on ACE activity and plasma renin activity levels in chronic heart failure patients. 82 In addition, proliferating infantile hemangioma expressed two essential components of the RAS, namely ACE and the AT II receptor, that accounted for the propranolol-induced accelerated involution of large proliferating infantile hemangioma. [83] [84] [85] Thus, taken together, these findings suggest that the RAS is activated in cancer patients and β-adrenergic blockers may play a role in cancer by modulating the RAS.
The transcription factor NF-κB is a hetero-dimeric, sequence-specific transcription factor that is expressed in many cell types. NF-κB has been implicated in chronic inflammatory diseases and is a key regulator of genes that are involved in responses to infection, inflammation, and stress. The NF-κB family of transcription factors plays a crucial role in inflammation as well as in the development and progression of cancer. The NF-κB pathway is dysregulated in prostate cancer and has been implicated in the progression to the androgen-independent state that ultimately leads to patient death. 86 NF-κB activity has been correlated with the progression and prognosis of pancreatic cancer in a mouse model. 87 NF-κB expression was higher in renal cancer specimens than in a control group, 88 and NF-κB is known to play an important role in endometrial cancer pathogenesis. 89 NF-κB signaling is important for medulloblastoma tumor growth, and the inhibition of NF-κB reduced tumor size and viability in vivo. 90 It has been reported that the association of the RE-1-silencing transcription factor with NF-κB increases risks of CRC, colon cancer, and rectal cancer. 91 NF-κB alleles are associated with oral carcinogenesis. 92 NF-κB 1 and NF-κBIA polymorphisms are associated with an increased risk for sporadic colorectal cancer in a southern Chinese population. 93 A homozygous NFκBα rs17103265 deletion is a novel genetic risk factor for gastric carcinogenesis, particularly for the development of certain subtypes of gastric cancer in a southern Chinese population. 94 NF-κB 1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in Chinese populations. 95 The functional NF-κB 1 -94 insertion/ deletion ATTG (adenine-thymidine-thymidine-guanine) polymorphism was associated with cervical squamous-cell carcinoma, particularly in individuals who were 35 years of age or younger. 96 A meta-analysis revealed that a common insertion/deletion (NF-κB 1 -94 insertion/ deletion ATTG, rs28362491) polymorphism in the NF-κB 1 gene might be associated with a decreased cancer risk, especially in Asian populations. 97 Moreover, cardiac collagen volume fraction and apoptotic cell numbers were elevated in ketaminetreated rats compared with control animals; these effects were prevented by the co-administration of metoprolol. The NF-κB cells were increased after ketamine treatment and sharply reduced after metoprolol administration. 98 Carvedilol submit your manuscript | www.dovepress.com Dovepress Dovepress blocked in vitro human peripheral blood T-cell activation by downregulating NF-κB activity. 99 Propranolol repressed gastric cancer cell growth through downstream NF-κB.
21,32 Beta 2 -adrenergic antagonists suppressed the activation of NF-κB 100 and potentiated the antiproliferative effects of gemcitabine by inducing apoptosis in pancreatic cancer cells. 30 Taken together, the evidence indicates that β-adrenergic antagonists may suppress NF-κB activation in cancer.
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear protein that contributes to both cell death and survival under stressful conditions. PARP-1 catalytic activity is stimulated by DNA strand breaks. Parp-1-deficient cells exhibited enhanced sensitivity to the lethal effects of ionizing radiation and alkylating agents, 101 whereas Parp-1 knock-out mice developed spontaneous mammary and liver tumors. 102, 103 The overexpression of PARP-1 has been reported in Ewing's sarcoma, 104 malignant lymphomas, 105 CRC, 106 HCC, 107 breast cancer, 108 pediatric central nervous system tumors, 109 and ovarian cancer. 110 In a meta-analysis, PARP-1 mRNA expression was correlated with higher grades, medullary histological types, tumor sizes, worse metastasis-free survival rates, and decreased overall survival rates in human breast cancer.
111 PARP-1 polymorphisms have been associated with gastric cancer, 112 prostate cancer, 113 esophageal squamous-cell carcinoma, 114 and lung cancer 115 in Han Chinese individuals but with a reduced risk of non-Hodgkin lymphoma in Korean males. 116 PARP-1 polymorphism reduced PARP-1 catalytic activity by 30%-40%. 117 A meta-analysis found no significant association between PARP-1 V762 polymorphism and cancer risk. However, the A variant allele of the PARP-1 V762 polymorphism was associated with an increased risk of cancer among the Asian population but a decreased risk among Caucasians, particularly with respect to glioma. 118 Moreover, rabbits treated with ketamine exhibited decreased left ventricular ejection fractions, reduced ventricular conduction velocity, and increased susceptibility to ventricular arrhythmia. Metoprolol treatment prevented these pathophysiological alterations. The expression of PARP-1 and apoptosis-inducing factor were increased after ketamine treatment and sharply reduced after metoprolol administration. 98 Propranolol treatment markedly suppressed PARP activation in the skeletal muscle biopsies of pediatric burn patients. 119 Propranolol also protected against staurosporine-induced DNA fragmentation and PARP cleavage in SH-SY5Y neuroblastoma cells. 120 The nonselective β-blocker carvedilol significantly inhibited apoptosis and suppressed activated PARP-1 cleavage in human cardiac tissue. 121 Carvedilol significantly decreased ischemiareperfusion-induced poly-and mono(ADP-ribosyl)ation in heart perfusion and in a rheological model. 122 Carvedilol also decreased PARP activity in the hippocampus and protected neurons against death after transient forebrain ischemia. 123 Metipranolol blunted sodium nitroprusside-induced breakdown of PARP-1 in rat eyes and retinas. 124 These findings suggest that PARP-1 is activated in cancer patients and β-adrenergic antagonists may have an effect on cancer by suppressing PARP-1.
Angiogenesis is a complex process that involves the coordinated steps of endothelial cell activation, proliferation, migration, tube formation, and capillary sprouting and requires the participation of many intracellular signaling pathways. VEGF is a key mediator of angiogenesis. Vascular changes associated with angiogenesis typically occur in cancer, but they have also been reported in inflammatory diseases. Statistically significant increases in VEGF expression relative to normal tissue have been reported in gastric cancer tissue, 125 inflammatory breast cancer, 132 and ovarian cancer. 133 VEGF polymorphisms were found to be a critical risk factor for genetic susceptibility to lung cancers in the ethnic Han Chinese of North China. 134 VEGF-A-1154GG genotype was considered to be a prognostic marker of poor survival in advanced-stage oral squamous-cell carcinoma patients.
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A meta-analysis has suggested that the VEGF-460T/C, VEGF-634G/C, and VEGF-2578C/A gene polymorphisms are associated with CRC. 136 A weak association between the VEGF+405G/C polymorphism and malignancy susceptibility was reported in an African population. 137 VEGF-A and VEGF-D overexpression suggested poor prognosis in patients with gastric cancer 138 and VEGF was identified as a marker of poor prognosis for patients with head and neck cancer. 139 NE and isoproterenol significantly enhanced VEGF production in the ovarian cell lines and cultured NPC tumor cells. These effects were blocked by the β-adrenergic antagonist propranolol, supporting a role for β-adrenergic receptors in these effects. NE also induced the invasiveness of all NPC cell lines in a dose-dependent manner, which was blocked by propranolol. 140, 141 Propranolol significantly decreased VEGF activity in a phorbol myristate acetate-activated human leukemic cell line. 142 Further, propranolol repressed gastric cancer cell growth through downstream effects on VEGF. 21, 31 NE increased the expression of VEGF and this effect was inhibited by propranolol in pancreatic cancer cells. 100, 143 In addition, epinephrine enhanced the expression of VEGF in colon adenocarcinoma cells. The stimulatory action of submit your manuscript | www.dovepress.com Dovepress Dovepress adrenaline on colon cancer growth was blocked by atenolol and ICI-118,551, which are β 1 -and β 2 -selective antagonists, respectively. 143 These findings suggest that β-adrenergic antagonists may modulate VEGF expression in cancer.
The reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) enzyme complex mediates critical physiological and pathological processes including cell signaling, inflammation, and mitogenesis through the generation of reactive oxygen species (ROS) from molecular oxygen. It has been demonstrated that NOX1 is required for Ras oncogene-induced cell transformation. 144 The NOX subunit p22 phox was reported to inhibit the function of the tumor suppressor protein tuberin in renal carcinoma cells. 145 The activation of NOXs has been demonstrated in the development of numerous cancers, including melanoma, 146 leukemia, 147 160 postmenopausal breast cancer, 161 and gastric cancer. 162 Moreover, nebivolol, a third-generation selective β-adrenoreceptor, improved left ventricle dysfunction and survival early after myocardial ischemia and inhibited cardiac NOX activation. 163 Treatment with nebivolol was associated with improvement in insulin resistance, reduced proteinuria, and decreased NOX activity/levels of ROS in kidney and skeletal muscle tissue in the transgenic TG(mRen2)27 rat. 164, 165 Nebivolol also improved diastolic relaxation, fibrosis, and remodeling in Zucker obese rats, with reductions in NOXdependent superoxide. 166 Carvedilol attenuated the increased protein expression of NOX subunits in the heart and kidney in daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. 167 NOX activity in whole blood and isolated neutrophils was inhibited in a dose-dependent manner by nebivolol, whereas atenolol, metoprolol, and carvedilol were markedly less effective in Watanabe heritable hyperlipidemic rabbits. 168 Celiprolol, a specific β 1 -antagonist with weak β 2 -agonistic action, suppressed NOX p22 phox , p47 phox , gp91 phox , and NOX1 expression in the left ventricle of deoxycorticosterone acetatesalt hypertensive rats. 169 Thus, taken together, findings suggest that β-adrenergic antagonists may have a role in cancer by suppressing NADPH expression.
The role of β-adrenergic blockers in cancer
Matrix metalloproteinases (MMPs) are proteolytic enzymes that are responsible for extracellular matrix remodeling and the regulation of leukocyte migration through the extracellular matrix, an important step in inflammatory and infectious pathophysiology. MMPs are produced by many types of cells, including lymphocytes, granulocytes, astrocytes, and activated macrophages. Activation of MMPs contributes to tumor angiogenesis and metastasis. MMP-1 expression has been linked to sarcoma cell invasion. 170 MMP-2 expression has been found increased in gastric cancer cells 125 and CRC. 171 MMP-9 was shown to be expressed in many cancer cells, including those associated with NSCLC, 172 lymph node metastasis in human breast cancer, 173 ovarian cancer invasion and metastasis, 174 glioblastoma multiforme, 175 and adamantinous craniopharyndioma. 176 The secretion of MMP-2 and MMP-9 by leukemic cells increased the permeability of the blood-brain barrier of the central nervous system by disrupting tight junction proteins. 177 In gastric cancer, MMP-2 and MMP-9 were shown to play important roles in tumor invasion and metastasis. 178 The risks for the development of hypophyseal adenoma and cervical neoplasia were greater in patients with MMP-1 polymorphisms 179, 180 than in those with the wild-type allele. The MMP-2 polymorphism contributed to prostate cancer susceptibility in Northern India 181 and to the clinical outcomes of Chinese patients with NSCLC treated with first-line platinum-based chemotherapy. 182 The MMP-7 polymorphisms were associated with esophageal squamous-cell carcinoma, gastric cardiac adenocarcinoma, NSCLC, and CRC. 115, 160, 183 The single-nucleotide polymorphisms (SNPs) in the MMP-2 and MMP-9 region are associated with susceptibility to head and neck squamous-cell carcinoma in an Indian population. 184 The SNPs of genes encoding MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, and MMP-21) were shown to be related to breast cancer risk, progression, and survival. 185 Based on a meta-analysis, an MMP-2 allele (-1306T) may be a protective factor against digestive cancer risk. 186 The MMP-9 polymorphism was associated with a lower risk of CRC 187 and polymorphisms in the promoter regions of MMP-1, MMP-3, MMP-7, and MMP-9 were associated with metastasis in certain cancers. 188 A meta-analysis revealed that polymorphisms of MMP-1 (-1607) and MMP-3 (-1612) increase the risk of CRC. 189 Moreover, propranolol inhibited tubulogenesis of human brain endothelial cells and MMP-9 secretion. 190 A selective β 3 -adrenoceptor agonist prevented human myometrial remodeling and the activation of MMP-2 and MMP-9 in an in vitro model of chorioamnionitis. 191 NE treatment increased MMP-2 and MMP-9 levels in cultured NPC tumor cells, which was inhibited by propranolol. NE also induced the invasiveness of all NPC cell lines in submit your manuscript | www.dovepress.com Dovepress Dovepress a dose-dependent manner, which could be blocked by an MMP inhibitor and propranolol. 141 Propranolol significantly decreased MMP-2 activity in a phorbol myristate acetateactivated human leukemic cell line. 142 Propranolol-induced growth inhibition was associated with G 0 /G 1 arrest, G 2 /M arrest, and repressed gastric cancer cell growth through the downstream inhibition of MMP-2 and MMP-9.
21 NE increased the expression of MMP-2 and MMP-9 and these effects were inhibited by propranolol in pancreatic cancer cells. 100, 192 Epinephrine upregulated MMP-9 activity in human colon adenocarcinoma HT-29 cells, which was blocked by atenolol, a β 1 -selective adrenergic antagonist, or ICI-118,551, a β 2 -selective adrenergic antagonist. 143 These studies suggested that β-adrenergic antagonists may play an important role in the pathological process of cancer by downregulating the level of MMPs and regulating the level of tissue inhibitors of metalloproteinases.
The MAPK pathways provide a key link between the membrane-bound receptors that receive these cues and changes in the pattern of gene expression, including the ERK cascade, the stress-activated protein kinases/c-jun N-terminal kinase (JNK) cascade, and the p38 MAPK/high osmolarity glycerol HOG cascade. 193 MAPK activation was higher in renal cancer specimens than in control group specimens. Renal tumor diameter and grade increase were directly correlated with p38 MAPK expression. 90 The p38 levels were significantly higher in the HCC patients with a larger tumor ($3 cm) and satellite tumors, and were significantly correlated with p-JNK levels. High p38 and low p-JNK expression was associated with poor survival in HCC patients. 194 Increased MAPK activity and mitogen-activated protein kinase phosphatase-1 overexpression were associated with the carcinogenesis of human gastric adenocarcinoma. 195 Overexpression of the Ras and MAPK proteins (Ras p21, ERK-1, JNK-1, and p38) conferred a progressive tendency toward invasive growth, advanced-stage cancer, and decreased levels of estrogen receptor-α protein in advancedstage human breast cancer. 196 The MAPK pathway was shown to be critical to oncogenic signaling in the majority of patients with malignant melanoma. 197 The tumor suppressive actions of transforming growth factor beta-1 decreased cell viability and induced apoptosis in invasive prostate cancer and bladder cancer cells via the Akt-independent, p38 MAPK, and stress-activated protein kinases/JNKmediated activation of caspases. 198 Genetic variation in the MAPK-signaling pathway influenced colorectal cancer risk and survival after diagnosis. 199 Expression of the MAPK phosphatase DUSP4 was associated with microsatellite instability in CRC and caused increased cell proliferation. 200 Moreover, the stimulation of β-adrenoceptors can activate cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) and mitogen-activated protein kinase (MAPK) pathways in pancreatic cancer cells. Pathways in pancreatic cancer cells. The β 2 -adrenergic antagonists suppressed invasion and proliferation by inhibiting both cAMP/PKA and Ras, which regulate activation of the MAPK pathway. 100 NE stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of the p38 MAPK pathway. These stimulatory effects were completely stopped by propranolol or p38 MAPK-inhibitor SB203580. 201 Propranolol was shown to exert its suppressive effects on hemangiomas through the hypoxia-inducible factor-1α-VEGF-A-angiogenesis axis, with effects mediated by the phosphoinositide 3-kinase/Akt and p38 MAPK pathways. 202 Thus, these findings suggest that β-adrenergic antagonists may have a role in cancer by suppressing the MAPK pathway.
Prostaglandins play a role in inflammatory processes. COX participates in the conversion of arachidonic acid into prostaglandins. Tumor inflammation is now recognized as one of the hallmarks of cancer. The overexpression of COX-2 is associated with resistance to apoptosis, increased angiogenesis, and increased tumor invasiveness in various cancers. Increased COX-2 expression was reported in endometrial adenocarcinoma, 203 breast cancer, 204 reno-medullary interstitial cell tumor, 205 CRC, 206 gastric cancer, 207 carcinoma of the cervix, 208 and familial adenomatous polyposis. 209 The deletion of COX-2 in mouse mammary epithelial cells delayed breast cancer onset. 210 COX-2 inhibitors also decreased the growth and induced regression of human esophageal adenocarcinoma xenografts in nude mice 211 and retarded murine mammary tumor progression by reducing tumor cell migration, invasiveness, and angiogenesis. 212 Genetic variability in enzymes could have an impact on the disease risk. COX-2 polymorphisms were reported to be associated with bladder cancer, 213 biliary tract cancer, 214 lung cancer, 215 nonmelanoma skin cancer after organ transplantation, 216 esophageal squamous-cell carcinoma, 217 NPC, 218 pancreatic cancer, 219 invasive ovarian carcinoma, 220 breast cancer, 221 gastric carcinoma, 222 acute myeloid leukemia, 223 prostate cancer, 224 head and neck cancer, 225 colorectal adenoma, 226 and HCC. 227 In a meta-analysis, the COX-2 1195G.A polymorphism was significantly associated with an increased risk for digestive system cancers, particularly in Asian populations. 228 In addition, the COX-2 -765G.C polymorphism may have caused an increased risk of CRC and esophageal cancer in patients of Asian descent, whereas the 8473T.C polymorphism may have caused a decreased risk of breast and lung cancer. 229 In submit your manuscript | www.dovepress.com Dovepress Dovepress addition, prostaglandin E 2 (PGE 2 ) has been reported to be associated with colorectal adenoma, 230 pancreatic tumor, 231 and childhood neuroblastoma. 232 Suppression of PGE 2 receptors inhibited human lung carcinoma cell growth. 233 Moreover, adrenaline increased PGE 2 release in human colon adenocarcinoma HT-29 cells, which can be blocked by COX-2 inhibitor or by atenolol, a β 1 -selective adrenergic antagonist, or ICI-118,551, a β 2 -selective adrenergic antagonist. 143 The β 2 -adrenergic antagonists suppressed COX-2 expression in pancreatic cancer cells. 100 Propranolol inhibits cell proliferation and represses gastric cancer cell growth through the downstream COX-2 pathway. 21, 32 In addition, propranolol and COX-2 inhibitor administration, which can be applied perioperatively in most cancer patients with minimal risk and at low cost, counteracted several immunologic and endocrinologic perturbations and improved recurrence-free survival rates in mice undergoing primary tumor excision. 234, 235 Celiprolol activates endothelial nitric oxide synthase (NOS) through the phosphatidylinositol 3-kinase/Akt pathway via NF-ĸB induced by oxidative stress. 169 These findings suggest that β-adrenergic antagonists may play a role in modulating the inflammatory process in cancer.
ROS play a major role in various cell-signaling pathways. ROS activate various transcription factors and increase the expression of proteins that control cellular transformation, tumor cell survival, tumor cell proliferation and invasion, angiogenesis, and metastasis. ROS have been shown to play an important role in the initiation and progression of many cancers. [236] [237] [238] [239] [240] [241] SNPs of antioxidant defense genes may significantly modify the functional activity of encoded proteins. Women with genetic variability in the iron-related oxidative stress pathways may be at increased risk for postmenopausal breast cancer. 242 The ala variant of superoxide dismutase was associated with a moderately increased risk of prostate cancer. 243 Based on a meta-analysis, manganese superoxide dismutase polymorphisms may contribute to cancer development (Val-9Ala) 244 and prostate cancer susceptibility (Val-16Ala) 245 but not to breast cancer susceptibility 246 (Val-16Ala). Moreover, myocardial tissue sections revealed increased ROS after traumatic brain injuries. Treatment with propranolol decreased ROS levels. 247 Carvedilol can modulate ROS-induced signaling. Carvedilol significantly decreased the ischemia-reperfusion-induced free-radical production and nicotinamide adenine dinucleotide catabolism, and decreased the lipid peroxidation and red blood cell membrane damage as determined by free malondialdehyde production in heart perfusion and in a rheological model. 120 Nebivolol improved diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. 248 These findings suggest that β-adrenergic antagonists modulate oxidative stress in cancer. NOS is an enzyme that is involved in the synthesis of nitric oxide (NO), which regulates a variety of important physiological responses including cell migration, immune response, and apoptosis. NO and calcium were reported to regulate mitochondrial biogenesis in follicular thyroid carcinoma cells. 249 There is a link between NO and the induction of apoptotic cell death in head and neck squamouscell carcinoma. 250 Cytokines, especially interferon-gamma, induced apoptosis in acute leukemia via the NO and caspase-3 pathways. 251 The reduction of NO levels enhanced the radiosensitivity of hypoxic NSCLC. 252 Increased NO may be a sign of subclinical cardiotoxicity of doxorubicin. 253 High NO concentrations at the periphery of a melanoma may contribute to metastasis by stimulating cell proliferation, inhibiting apoptosis, or acting as a lymphangiogenic factor. 254 Inducible NOS mRNA expression was considerably higher in glioblastoma specimens than in meningioma specimens. 255 Inducible NOS expression has been correlated with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients 256 and estrogen receptor-negative breast cancer patients. 257 NOS inhibition enhanced the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. 258 NOS polymorphisms were reported to be associated with bladder cancer, 259 urothelial carcinoma, 260 gastric cancer, 261 colorectal cancer, 262 and nonHodgkin's lymphoma. 263 In a meta-analysis, endothelial NOS 894G.T polymorphism was associated with breast cancer. 264 Moreover, metipranolol blunted NO-induced lipid peroxidation in rat eyes and retinas. 114 Nebivolol prevented vascular NOS III uncoupling in experimental hyperlipidemia. 168 Propranolol suppressed hemangioma growth by inhibiting the expression of endothelial NOS protein and the subsequent production of NO. 265 These findings suggest that β-adrenergic antagonists may have a role in cancer by inhibiting the expression of NOS.
Conclusion
Beta-adrenergic blockade may play a role in the prevention and treatment of cancer. Genetic studies have provided the opportunity to determine the proteins that link β-adrenergic antagonism to cancer pathology. Beta-adrenergic inhibition also exerts its effect on cancer via non-genomic mechanisms. Further investigation of the relationship between β-adrenergic antagonists and cancer is required. 
